Background. In January 2012, Argentina included universal pneumococcal vaccination in the routine childhood vaccination program using a 13-valent pneumococcal conjugate vaccine (PCV13). A 2 + 1 schedule (2 doses in the first year of life and a booster dose at 12 months of age) in children aged <2 years and 2-dose catch-up immunization in children aged 13 to 24 months was administered during the first year of vaccine introduction. The purpose of this study was to assess the burdens of invasive pneumococcal disease (IPD) and/or community-acquired pneumonia (CAP) in hospitalized children younger than 5 years during the first 2 years of the program compared to those in the prevaccination period in our setting.
Acute respiratory tract infection is among the main causes of death in children [1] . It is estimated that 70% of all acute respiratory tract infection-related deaths result from pneumonia, which causes up to 2 million deaths per year worldwide in children younger than 5 years [2] . In addition, Streptococcus pneumoniae is the leading bacterial cause of pneumonia and represents a major cause of hospitalization and deaths worldwide. The World Health Organization estimates that approximately 1 million children die every year as a result of pneumococcal disease, and these potentially preventable deaths occur primarily in developing countries [3] [4] [5] [6] .
S pneumoniae is the main bacterial cause of community-acquired pneumonia (CAP) in children younger than 5 years in Argentina, in outpatient and inpatient settings [7, 8] , and is one of the most common causes of bacteremia and meningitis in pediatric patients after introduction of the Haemophilus influenzae type b conjugate vaccine in the 1990s.
Therefore, we decided to perform surveillance of invasive pneumococcal disease (IPD) and CAP in children younger than 5 years before and 2 years after introduction of the pneumococcal conjugate vaccine to gain a better understanding of the effect that the vaccination program had in our setting.
Universal pneumococcal vaccination was included in the national immunization program of Argentina in January 2012. The 13-valent pneumococcal conjugate vaccine (PCV13) was administered in a 2 + 1 schedule (2 doses in the first year of life [at 2 and 4 months of age] and a booster dose at 12 months of age) to children aged <2 years, and a 2-dose catch-up schedule was used for children aged 13 to 24 months during only the first year of program implementation.
The national ministry of public health reported that the coverage rate increased from 50%, on average, in 2012 to 94.5% for the first dose, 86.4% for the second dose, and 75% for the third (booster) dose in 2013.
The objective of this study was to show the effect that the universal pneumococcal vaccination program had in rapidly decreasing IPD and/or CAP disease burden caused by hospitalizations in children <5 years of age by comparing the surveillance data in the prevaccine (2009-2011) and postvaccine (2012-2013) periods.
MATERIAL AND METHODS
An epidemiologic surveillance study in pediatric patients younger than 60 months hospitalized as a result of IPD and/ or CAP was conducted between July 2009 and November 2013 in 5 pediatric centers located in different areas of Argentina: Hospital de Niños "Ricardo Gutiérrez" (Buenos Aires), Hospital de Niños "Santísima Trinidad" (Córdoba), Hospital de Niños "Orlando Alassia" (Santa Fe), Hospital Italiano Regional del Sur (Bahía Blanca), and Hospital Provincial "Dr. Eduardo Castro Rendón" (Neuquén).
The study protocol was authorized by the local institutional review boards and/or ethics committees and was conducted in compliance with the general principles of the recommendations guiding physicians in biomedical research involving human subjects contained in the original Declaration of Helsinki and all amendments and clarifications therein.
The study design included an interview with the parents of patients to be enrolled, data collection from the charts during hospitalization, and a visit or telephone contact 7 days after hospital discharge to evaluate acute disease sequelae.
An informed-consent form was obtained from each patient's parent or legal guardian to allow clinical and laboratory data collection. Hospitalized children (boys and girls) younger than 60 months whose parent/guardian gave consent were enrolled in the study. Children diagnosed with CAP and/or empyema in whom other pathogens during the first 3 days after admission were identified were excluded from the study.
The case definitions considered were as follows.
Invasive Pneumococcal Disease
The presence of S pneumoniae obtained by microbiological culture of normal sterile fluid such as blood, cerebrospinal fluid, or pleural, joint, or peritoneal fluid was required to define IPD.
Community-Acquired Pneumonia
Only cases of CAP were included. CAP was defined in any patient with clinical signs/symptoms of pneumonia and chest radiograph results consistent with pneumonia (lung consolidation and/or air bronchogram) with or without pleural effusion, acquired outside the hospital or extended-care facility, as was standardized by the World Health Organization Department of Vaccines and Biologicals [9] . If the presence of S pneumoniae was detected in a blood culture, the case was defined as pneumococcal CAP (P-CAP). Two attending physicians (1 of whom was blinded to the study) assessed the chest radiographs to define the eligibility criteria for enrollment at each center.
Empyema
Empyema was defined as a collection of purulent fluid in the pleural space associated with the underlying pneumonia. Purulent fluid had to meet at least 1 of the following criteria: lactate dehydrogenase concentration of >1000 U/L, a pH of <7.20, a glucose concentration of <40 mg/dL, increased cellularity with a high predominance of polymorphonuclear leukocytes, and/or bacteria seen on direct microscopic examination. Pneumococcal empyema (PE) was defined by the presence of S pneumoniae in blood and/or pleural fluid culture. S pneumoniae isolates obtained from normal sterile fluids (such as blood or pleural, cerebrospinal, peritoneal, or articular fluid) that could be saved were sent to a central microbiology laboratory at Hospital de Niños "Ricardo Gutiérrez" for serotyping. Pneumococcal antisera from the Staten Serum Institut in Denmark were used.
Statistical Analysis
Descriptive data are expressed as mean ± standard deviation (for quantitative variables) and number (percentage) (for categorical variables).
Admission rates and average annual rates per 10 000 hospitalizations with 95% confidence intervals (95% CIs) are described for each diagnostic category.
Categorical data were examined using the median test as appropriate and the nonparametric Mann-Whitney test for continuous variables. Statistical significance was defined as a P value of <.05. Stata 8.0 software (StataCorp, College Station, TX) was used to perform the statistical analyses. The average numbers of hospitalizations were 34 038 and 32 952 during periods 1 and 2, respectively. A total of 987 (64.6%) patients were younger than 24 months.
Demographic characteristics of the patients are shown in Table 1 . Children hospitalized as a result of IPD and/or CAP were statistically older during the second study period.
Regarding risk factors for pneumococcal disease, the prematurity rate was higher in the first period than in the second period (13.9% vs 8.2%, respectively), even if no other comorbidities were prevalent between periods. Taking into account the children's population, target of the vaccination program (children younger than 2 years), no statistical difference in the reduction of cases of CAP between children younger than 1 year versus those aged 1 to 2 years (P = .72) was found after routine PCV13 immunization during the first 2 years of program implementation.
P-CAP
We confirmed CAP by positive blood culture in 51 (4.5%) of 1120 patients from whom a blood sample was collected for culture. During the prevaccine period, 40 patients with P-CAP were admitted to the hospital (13.3 cases per year; hospitalization rate, 11.8 per 10 000 admissions [95% CI, 8.4-15.9 per 10 000 admissions]); however, this number decreased to 11 patients during period 2 (5.5 cases per year; hospitalization rate, 3.3 per 10 000 admissions [95% CI, 1.6-5.9 per 10 000 admissions]).
Empyema
A total of 249 empyema cases occurred during the 5-year study period, 176 in period 1 (average, 59 cases per year; hospitalization rate, 17.3 per 10 000 admissions [95% CI, 12.8-21.9 per 10 000 admissions]) and 73 in period 2 (average, 36 cases per year; hospitalization rate, 10.9 per 10 000 admissions [95% CI, 7.2-14.6 per 10 000 admissions]); therefore, the reduction in admissions resulting from empyema is 39% (P = .03), which is statistically significant. After PCV13 introduction, patients admitted as a result of empyema were significantly older than those included in the study during the first study period (34. PE was diagnosed by positive culture results from blood and/or pleural fluid in a total of 84 patients during the study, 68 (81%) in the first period and 16 (19%) in period 2 (after vaccine introduction). A total of 125 cases of pneumococcal pulmonary disease (P-PD) were included in the study. P-PD was defined as a case of P-CAP plus pneumococcal empyema. During period 1, a total of 110 patients were enrolled (36.6 per year; hospitalization rate, 10.9 per 10 000 admissions [95% CI, 7.2-14.5 per 10 000 admissions]); however, during period 2 this number decreased to 25 per year (average, 12.5 per year; hospitalization rate, 3.9 per 10 000 admissions [95% CI, 1.6-6.2 per 10 000 admissions]); therefore, we estimate a 67.8% reduction of P-PD (P < .001) after PCV13 introduction. Table 3 shows the overall reductions in IPD, CAP, and P-PD after PCV13 introduction in Argentina.
A total of 220 children with IPD (eg, P-CAP, PE, meningitis, pneumococcal bacteremia, peritonitis, arthritis) were enrolled during the study, 169 (76.8%) in period 1 and 51 (23.2%) in period 2; therefore, we observed a 50% reduction (P = .03) of IPD cases after implementation of the pneumococcal conjugate vaccine program.
During the first study period, 64.5% (731 of 1133) of cases of IPD and/or CAP occurred in children younger than 2 years, the target population of the vaccination program, whereas after vaccine introduction, the cases in this age group decreased to 55.7% (220 of 395). In older children (24-60 months), 35.5% (402 of 1133) of cases occurred during period 1, whereas in the second period, this percentage increased to 44.3% (175 of 395) (P = .002).
S pneumoniae is currently the most important bacterial agent that causes purulent acute meningitis in hospitalized children in our setting. During the study, a total of 38 children with pneumococcal meningitis were enrolled (23 [60.5%] of 38 in period 1 and 15 [39.5%] of 38 in period 2); the numbers of patients with pneumococcal meningitis in both periods were low (average, 8 cases per year in period 1 and 7 cases per year cases in period 2); therefore, a longer surveillance period is needed for children with this disease to assess the effectiveness of the pneumococcal conjugate vaccine to reduce the rate of hospitalizations that result from pneumococcal meningitis.
Moreover, no statistical analysis was performed for other manifestations of IPD because of their low incidences during the surveillance period; in periods 1 and 2, such manifestations included pneumococcal bacteremia (12 and 7, respectively), peritonitis (12 and 2, respectively), cellulitis (3 and 0, respectively), and arthritis (6 and 0, respectively). 9A, 9N, 12F, 15B, 19B, 20 , 22F, and 33F were each found once (7%). The most frequently found serotypes, which accounted for 70.5% (96) of isolates from all of the analyzed cases of IPD in the study period, were serotypes 14, 5, 1, and 6B, and variations in their incidences across the study are shown in Table 3 .
The incidence of most serotypes was reduced from period 1 to period 2 (49 to 9 ], respectively). However, the incidence of serotype 6A was increased (from 1 to 3) in the second period. In addition, some new serotypes (types 4, 15B, 20, and 22F) were detected in only the second period of study.
The hospital lengths of stay of the children admitted as a result of IPD and/or CAP were similar: 9.1 ± 10.3 versus 9.5 ± 11.5 days in the first and second study periods, respectively (P = .41). Furthermore, no differences in intensive care unit lengths of stay that resulted from IPD and/or CAP between the 2 periods were found (377 vs 353 days, respectively). According to these data, we should consider that although the number of admissions resulting from IPD and/ or CAP decreased, the severity of pneumococcal disease was similar in both periods.
IPD-and/or CAP-related procedures performed during each period were assessed. The number of thoracoscopies decreased from 24 to 4 (-83%) and pleural drainages from 138 to 56 (-59.4%) between periods 1 and 2. In addition, the incidence of pleural surgery (decortication) decreased from 45 to 23 (-48 .9%) between periods 1 and 2, and the number of central venous catheters used for these hospitalized children decreased from 81 to 51 (-37%).
The number of antimicrobial agent administration-days for IPD and/or CAP was evaluated (mean, 2095 days in period 1 vs 941 days in period 2), and a 44.9% reduction in the number of days under antibiotic treatment for pneumococcal disease and/ or CAP after PCV13 introduction was found. The IPD and/or CAP mortality rates were lower than 1% in both periods (5 of 1133 [0.4%] in period 1 and 3 of 395 [0.8%] in period 2).
DISCUSSION
IPD is one of the main lethal but vaccine-preventable diseases in children younger than 5 years worldwide. It is estimated that each year in Latin America, 20 200 to 33 100 children die as a result of pneumococcal disease, mainly pneumonia or meningitis [3] .
Universal vaccination with pneumococcal conjugate vaccine using PCV7 and the introduction of PCV13 have been shown to be effective in significantly reducing the incidence of IPD, pneumococcal pneumonia, and mucous membrane diseases such as acute otitis media in countries were the vaccine has been included in routine childhood vaccination programs [10] [11] [12] [13] . The effect of PCV7 vaccination using a priming of 3 doses plus 1 booster dose or a 2 + 1 dose has been demonstrated [14] [15] [16] [17] .
Mexico (in 2006), Uruguay (in 2008), and Brazil (2010) were the first countries in Latin America to introduce a pneumococcal conjugate vaccine in their routine immunization programs, and promising results were found [13, [18] [19] [20] [21] . Although these countries have used different conjugate vaccines (7-, 10-, and 13-valent, respectively), published data have reported the initial impact and effectiveness of conjugate vaccines on the incidence of pneumococcal disease in Latin American countries [22] [23] [24] [25] .
PCV13, using a 2 + 1 dose schedule (1 dose at 2 and 4 months and a booster dose at 12 months), was included in the national immunization program in Argentina in January 2012 for children younger than 2 years; in addition, a 2-dose catch-up schedule was used to children between 13 and 24 months of age (exclusively during the first year of program implementation) [26] .
This article reports the results of, to our knowledge, the largest multicenter surveillance study on IPD and/or CAP burden in hospitalized children younger than 60 months in different geographical areas in Argentina; the study began 3 years before vaccine introduction into the routine immunization program and continued for the first 2 years of pneumococcal vaccination to assess the effect of the vaccine on pneumococcal disease and CAP burden.
For comparisons between the prevaccination and postvaccination periods, an overall significant 50% reduction in hospitalizations resulting from IPD was observed. However, this reduction in disease burden was statistically different in children younger than 2 years versus older children (P = 0.002). These results are comparable with those found in other Latin American countries [11, 13, 15, 16, 27] .
Variations in serotype distributions during the study revealed that the incidence of most of the serotypes included in the PCV13 (all except type 6A), decreased in the second study period. Furthermore, some S pneumoniae serotypes were detected for the first time after the vaccination program was implemented, although their frequency was too low to make conclusions about their effect.
This study had some limitations, such as the fact that chest radiograph assessments were performed by 2 pediatricians (1 of whom was blinded to the study) instead of by a radiologist, as would have been desirable. Because the study period lasted only 2 years, the effect that the vaccination program had on less prevalent pneumococcal diseases, such as bacteremia, meningitis, and peritonitis, cannot be assessed.
The results of this study confirm previously reported results on the effect that vaccination with pneumococcal conjugate vaccine has on invasive disease burden in hospitalized patients. However, the study was innovative in showing the effect that the vaccine had in reducing the incidence of pneumococcal infection after surgical and invasive procedures in the second study period. We have also described the significant decrease in antibiotic use in cases of pneumococcal disease in hospitalized patients after inclusion of the PCV13 2 + 1 schedule, which reveals the effectiveness of the pneumococcal conjugate vaccine program in Argentina.
Notes
